We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
251
CALL
Apple
AAPL
$5.04T
– –
-16,212
Closed -$31.1M
AAPL icon
252
PUT
Apple
AAPL
$5.04T
– –
-16,212
Closed -$31.1M
ABUS icon
253
CALL
Arbutus Biopharma
ABUS
$847M
– –
-450
Closed -$967K
AGEN
254
CALL
Agenus
AGEN
$286M
– –
-77
Closed -$477K
AGEN
255
Agenus
AGEN
$286M
– –
-9,468
Closed -$548K
ALKS icon
256
Alkermes
ALKS
$8.12B
– –
-5,126
Closed -$236K
ALKS icon
257
PUT
Alkermes
ALKS
$8.12B
– –
-155
Closed -$683K
ATHE
258
CALL
Alterity Therapeutics
ATHE
$85.9M
– –
-50
Closed -$838K
ATHE
259
Alterity Therapeutics
ATHE
$85.9M
– –
-288
Closed -$48K
ATHE
260
PUT
Alterity Therapeutics
ATHE
$85.9M
– –
-4
Closed -$62K
BLUE
261
DELISTED
bluebird bio
BLUE
– –
-7,858
Closed -$2.52M
CASI
262
DELISTED
CASI Pharmaceuticals
CASI
– –
-106,522
Closed -$1.95M
CATX icon
263
Perspective Therapeutics
CATX
$320M
– –
-22,538
Closed -$496K
CORT icon
264
CALL
Corcept Therapeutics
CORT
$10B
– –
-400
Closed -$174K
CYTK icon
265
CALL
Cytokinetics
CYTK
$10.7B
– –
-661
Closed -$628K
FOCL
266
EDAP TMS S.A.
FOCL
$229M
– –
-23,200
Closed -$79.7K
EXAS
267
DELISTED
Exact Sciences
EXAS
– –
-54,000
Closed -$765K
EXAS
268
PUT
DELISTED
Exact Sciences
EXAS
– –
-655
Closed -$928K
GILD icon
269
Gilead Sciences
GILD
$167B
– –
-155,073
Closed -$12.1M
INSM icon
270
PUT
Insmed
INSM
$22.5B
– –
-305
Closed -$581K
INVA icon
271
Innoviva
INVA
$1.59B
– –
-42,853
Closed -$1.07M
INVA icon
272
PUT
Innoviva
INVA
$1.59B
– –
-666
Closed -$1.66M
IONS icon
273
CALL
Ionis Pharmaceuticals
IONS
$9.01B
– –
-1,584
Closed -$6.84M
IONS icon
274
PUT
Ionis Pharmaceuticals
IONS
$9.01B
– –
-2,078
Closed -$8.98M
IWM icon
275
PUT
iShares Russell 2000 ETF
IWM
$79.5B
– –
-890
Closed -$10.4M
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.